Skip to main content
SpringerLink
Log in

Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab

  • review article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Purpose

To analyze the clinical outcome of treatment with aflibercept in patients not responding to ranibizumab and bevacizumab.

Methods

Retrospective review of 32 eyes from 30 consecutive patients with choroidal neovascularization (CNV) who showed no response to treatment with ranibizumab or bevacizumab and were switched to aflibercept. Visual acuity, central macular thickness (CMT) and presence or absence of intraretinal or subretinal fluid were analyzed before switching to aflibercept, after each of three uploading dose injections of aflibercept and 6, 8 and 10 weeks after the third aflibercept injection. All eyes had previous ranibizumab injections and the mean number of previous injections was 14.75 (± 7.38). Mean duration of previous anti-vascular endothelial growth factor (VEGF) treatment was 38 months (± 27.35 months).

Results

Mean visual acuity before switching to aflibercept was 0.40 ± 0.30 logMAR. After the third injection visual acuity was 0.3 ± 0.3 logMAR and 10 weeks after the third injection it was 0.50 ± 0.20 logMAR. No significant differences were seen during treatment and follow-up. The mean CMT was 394 ± 118 µm at baseline, at follow-up (first, second and third, group week 6, group week 8 and group week 10) it was 317 ± 108 µm, 301 ± 99 µm, 292 ± 83 µm, 270 ± 78 µm, 340 ± 146 µm and 377 ± 92 µm, respectively. Significant reductions in CMT were seen between the first and third follow-up injections and at group week 8. Of the patients 59.4 % were complete non-responders to aflibercept.

Conclusion

Aflibercept results in improvement in CMT in non-responders to ranibizumab and bevacizumab as long as therapy is given continuously and can therefore be an alternative therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brucker AJ. Age-related macular degeneration. Retina. 2009;(6 Suppl):S2–S4. doi:10.1097/IAE.0b013e3181ad255f.

    Google Scholar 

  2. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol. 2004;88(10):1270–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol. 1993;111(9):1200–9.

    Article  Google Scholar 

  4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44.

    Article  CAS  PubMed  Google Scholar 

  5. Comparison of Age-related Macular Degeneration Treatmens Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–98.

    Article  Google Scholar 

  6. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3115–20.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachphylaxis after intravitreal bevacizumab for exsudative age-related macular degeneration. Retina. 2009;29(6):723–31.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab and aflibercept (vascular endothelial growth factor Trap Eye). Retina. 2012;32:434–57.

    CAS  PubMed  Google Scholar 

  9. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Opththalmol. 2008;92(5):667–8.

    Article  CAS  Google Scholar 

  11. Nguyen QD, Heier J, Brown D, et al. Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF trap-eye in wet AMD: one-year results of the View-1 study Invest Ophthalmol Vis Sci. 2011;52:E-Abstract 3073.

  12. Schmidt-Erfurth U, Chong V, Kirchof B, et al. Primary results of an international phase III study using intravitreal VEGF trap-eye compared to ranibizumab in patients with wet AMD (VIEW 2). Invest Ophthalmol Vis Sci. 2011;52:E-Abstract 1650.

  13. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156:15–22.

    Article  CAS  PubMed  Google Scholar 

  14. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156:23–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Am J Ophthalmol. 2014;121(1):188–92.

  16. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye. 2013;27:663–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.

    Article  PubMed  Google Scholar 

  18. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to Aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:29–35.

    Article  CAS  PubMed  Google Scholar 

  19. Cho H, Shah C, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on Ranibizumab and/or Bevacizumab. Br J Ophthalmol. 2013;97(8):1032–5.

    Article  PubMed  Google Scholar 

  20. Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.

    Article  PubMed  Google Scholar 

  21. Chang AA, Li H, Broadhead GK, et al. Intravitreal Aflibercept for treatment-resistant neovascular age-related macular degeneration. Am J Ophthalmol. 2014;121(1):188–92.

    Google Scholar 

  22. Heußen FMA, Shao Q, Ouyang Y, Joussen AM, Müller B. Klinische Ergebnisse bei Wechsel von Ranibizumab zu Aflibercept in Augen mit exsudativer AMD. Klin Monatsbl Augenheilkd. 2013;230:KV56.

    Article  Google Scholar 

  23. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33:1605–12.

    Article  CAS  PubMed  Google Scholar 

  24. Hall LB, Zebardast N, Huang JJ, Adelman RA. Alfibercept in the treatment of neovascular agerelated macular degeneration in previously treated patients. J Ocul Pharmacol Ther. 2014;30(4):346–52.

    Article  CAS  PubMed  Google Scholar 

  25. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156:15–22.

    Article  CAS  PubMed  Google Scholar 

  26. Ziegler M, Heimes B, Book B, Dietzel M, Zeimer M, Spital G, Gutfleisch M, Pauleikhoff D, Lommatzsch A. Ophthalmologe. 2015;112(5):435–43.

    Article  CAS  PubMed  Google Scholar 

  27. Schachat AP. Switching anti-vascular endothelial growth factor therapy for neovascular agerelated macular degeneration. Am J Ophthalmol. 2013;156:1–2.

    Article  PubMed  Google Scholar 

  28. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to Aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:29–35.

    Article  CAS  PubMed  Google Scholar 

  29. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96:1–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, KH Hietzing, Wolkersbergenstr. 1, 1130, Vienna, Austria

    Sandra Maksys MD, Sibylla Richter-Müksch MD, Birgit Weingessel MD & Pia Veronika Vécsei-Marlovits MD, MSc, MBA

  2. Karl Landsteiner Institute, Department of process enhancement and quality management in cataract surgery, KH Hietzing, Wolkersbergenstr. 1, 1130, Vienna, Austria

    Sandra Maksys MD, Sibylla Richter-Müksch MD, Birgit Weingessel MD & Pia Veronika Vécsei-Marlovits MD, MSc, MBA

Authors
  1. Sandra Maksys MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sibylla Richter-Müksch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Birgit Weingessel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pia Veronika Vécsei-Marlovits MD, MSc, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sibylla Richter-Müksch MD.

Ethics declarations

Conflict of interest

S. Maksys, S. Richter-Müksch, B. Weingessel, and P.V. Vécsei-Marlovits declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maksys, S., Richter-Müksch, S., Weingessel, B. et al. Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab. Wien Klin Wochenschr 129, 351–357 (2017). https://doi.org/10.1007/s00508-016-1055-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-016-1055-0

Keywords

Search

Navigation